# Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma

> **NCT00003505** · PHASE2 · WITHDRAWN · sponsor: **Burzynski Research Institute**

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** antineoplaston A10
- **DRUG:** antineoplaston AS2-1
- **PROCEDURE:** alternative product therapy
- **PROCEDURE:** biological therapy
- **PROCEDURE:** biologically based therapies
- **PROCEDURE:** cancer prevention intervention
- **PROCEDURE:** complementary and alternative therapy
- **PROCEDURE:** differentiation therapy

## Key facts

- **NCT ID:** NCT00003505
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003505, "Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*